Scarica l'app Stockscreener
0.00
100.00%
-14.49
Dopo l'orario di chiusura:
14.49
14.49
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Goldman Sachs (FOLD) discloses 16.78M shares, 5.3% ownership (Schedule 13G) - Stock Titan
Fabry Disease Treatment Market to Reach USD 3,530.5 Million - openPR.com
BioMarin Q1 earnings miss, sales beat, '26 revenue guidance raised - MSN
Amicus Therapeutics (Delisted) | SCHEDULE 13G: Others - Moomoo
UBS Group-affiliated funds hold 17.14M shares in Amicus Therapeutics (NASDAQ: FOLD) - Stock Titan
[15-12G] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Which Is a Better Investment, AnaptysBio, Inc. or Amicus Therapeutics, Inc. Stock? - AAII.com
MSN Money - MSN
BioMarin acquires Amicus Therapeutics for $4.8bn - MSN
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com South Africa
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
BioMarin Reports First Quarter 2026 Financial and Operating Results - Santa Maria Times
UBS Group AG Grows Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
CM Management LLC Has $5.27 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - Sahm
Glazer Capital (FOLD) reports zero holdings after falling below 5% stake - Stock Titan
Pictet Asset Management Holding SA Trims Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Decreases Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust - Sahm
[EFFECT] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Amicus Therapeutics (FOLD) Expected to Announce Earnings on Thursday - MarketBeat
Amicus Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Vanguard Capital Management holds 5.20% of Amicus Therapeutics (NASDAQ: FOLD) - Stock Titan
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from S&P Global BMI Index - marketscreener.com
Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
BioMarin closes $4.8B Amicus deal to boost rare disease portfolio - MSN
Net current asset value per share of Amicus Therapeutics, Inc. – BIVA:FOLD - TradingView
Amicus Therapeutics Hits New 52-Week High at $14.50 - Markets Mojo
Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Amicus Therapeutics (NASDAQ: FOLD) director’s shares and options cashed out in BioMarin deal - Stock Titan
Amicus Therapeutics (FOLD) director cashes out stock and options in BioMarin deal - Stock Titan
BioMarin deal pays Amicus (NASDAQ: FOLD) director $14.50 per share - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) director cashes out equity in BioMarin deal - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) director equity paid out at $14.50 in BioMarin deal - Stock Titan
Director at Amicus (NASDAQ: FOLD) exits stake in BioMarin deal - Stock Titan
BioMarin-Amicus deal pays out Amicus (NASDAQ: FOLD) director - Stock Titan
BioMarin acquisition cashes out Amicus (FOLD) director’s shares and options - Stock Titan
Amicus Therapeutics (FOLD) CAO exits stock and options in BioMarin deal - Stock Titan
BioMarin-Amicus deal pays CDO Castelli (FOLD) $14.50 per share - Stock Titan
Amicus Therapeutics (FOLD) CPO equity fully cashed out at $14.50 deal price - Stock Titan
Amicus (FOLD) chief legal officer exits equity as BioMarin buyout pays $14.50 - Stock Titan
Amicus Therapeutics (FOLD) CFO exits equity as BioMarin acquisition closes - Stock Titan
Amicus Therapeutics (FOLD) CEO disposes 1.0M shares, options in BioMarin merger - Stock Titan
BioMarin completes $4.8B acquisition of Amicus Therapeutics - Investing.com UK
Amicus Therapeutics Q3 2025 Earnings Preview - MSN
[POS AM] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) taken private in $14.50-per-share cash merger - Stock Titan
[POSASR] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
BioMarin Pharmaceutical Closes $4.8 Billion Acquisition of Amicus Therapeutics - marketscreener.com
BioMarin completes $4.8B acquisition of Amicus Therapeutics By Investing.com - Investing.com South Africa
Amicus Therapeutics withdraws Nasdaq listing | FOLD SEC FilingForm 25-NSE - Stock Titan
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):